InvestorsObserver is giving SAB Biotherapeutics Inc (SABS) an Analyst Rating Rank of 74, meaning SABS is ranked higher by analysts than 74% of stocks. The average price target for SABS is $19.375 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating SABS a Strong Buy today. Find out what this means to you and get the rest of the rankings on SABS!